Serum CHI3L1 has already been recommended at international professional conferences as a noninvasive diagnostic technology for liver fibrosis and has been included in the “Guidelines on the Management of Hepatic Encephalopathy in Cirrhosis” of the Chinese Medical Association (2018) and the “Guidelines on the Prevention and Treatment in Chronic Hepatitis B” of the Chinese Medical Association (2019) [27, 28]. Here, CHI3L1 is linked to Cirrhosis.